GBIO FY2024 SEC EDGAR DEF 14A

Generation Bio Co. CEO pay ratio

The CEO earned $1.7M in FY2024 against median worker pay of $218,104 · Chemicals & Pharmaceuticals.

State
MA
Filing date
2025-04-23
Industry
Chemicals & Pharmaceuticals
Fiscal year
FY2024

Data updated August 2026

Subscribe to Generation Bio Co. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
8:1
Below Average (Scale: 0–1000:1)
CEO pay
$1.7M
Median worker
$218,104

Latest filing FY2024. This company's newest DEF 14A on file is for FY2024, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.

Answer first

Generation Bio Co. reported a 8:1 CEO-to-worker pay ratio in FY2024 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.

Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Pay ratio
8:1
FY2024 disclosed
CEO total
$1.7M
Summary Compensation Table total
Median worker
$218,104
Dodd-Frank median employee

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2024

A component-level pay breakdown is not reported in Generation Bio Co.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Generation Bio Co.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2024. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
8:1
FY2024
vs prior FY
-4:1
from FY2023 12:1
CEO $ YoY
-26%
$1.7M latest
Filings shown
4
FY2021–2024
Generation Bio Co. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $5.9M - $219,002 27:1 -
2022 $4.0M -32% $235,454 17:1 -10:1
2023 $2.4M -41% $196,110 12:1 -5:1
2024 $1.7M -26% $218,104 8:1 -4:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1733294, FY2021–2024. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
8:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$1.7M
Companies in Industry
168
vs. Industry Median
Below

Generation Bio Co.: near-parity Item 402(u) ratio

Generation Bio Co. stamps FLOOR · ELITE-MED at 8:1 against $218,104 median worker pay in FY2024. the CEO earned 8× the median employee ($218,104) in FY2024.

At $218,104 median worker pay, the FLOOR stamp is near pay-parity territory under LIGHT CEO total.

CEO Total Pay

$1.7M

FY2024 Summary Compensation, below median

Pay Ratio

8:1

Below typical

What FY2024 shows for Generation Bio Co.

Generation Bio Co. stamps FLOOR · ELITE-MED at 8:1 against $218,104 median worker pay in FY2024. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Generation Bio Co.'s $1.7M CEO total is at or below the $7.9M industry median CEO pay.

Generation Bio Co. stamps FLOOR · LIGHT · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2024

Total Compensation
$1.7M
Median Employee Pay
$218,104
Pay Ratio
8:1
Filing Date
2025-04-23

Company Info

Ticker
GBIO
CIK
1733294
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
MA
SEC EDGAR DEF 14A for CIK 1733294, FY2024. Informational only, not investment advice. Verify on EDGAR.

Read with Generation Bio Co.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · LIGHT · ELITE-MED.

Data sourced from SEC EDGAR DEF 14A for Generation Bio Co. (CIK 1733294), FY2024. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.